


Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV341079272US) in an envelope addressed to:

Mail Stop: Patent Application Commissioner for Patents,  
PO Box 1450, Alexandria, VA 22313-1450  
on this 17th day of July 2003.

s/

Danielle Dixon



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re the Application of:**  
**Steven Lee Bender et al.**

**Serial No.:** Not Yet Assigned

**Filed:** Herewith

**For:** AMIDE COMPOUNDS AND  
PHARMACEUTICAL COMPOSITIONS FOR  
INHIBITING PROTEIN KINASES, AND  
METHODS FOR THEIR USE

**Group Art Unit:** 1624

**Examiner:** HABTE, KAHSAY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Mail Stop: Patent Applications  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the art documents listed on the attached Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified at 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached Form PTO-1449 and returning a copy of the initialed form to Applicant.


Copies of the cited documents are not enclosed since they were previously cited by or submitted to the PTO in Application Serial No. 09/764,306, filed January 19, 2001 upon which the present application relies for priority benefit under 35 U.S.C. § 120.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified at 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Date:

July 17, 2003

Respectfully submitted,

  
Joseph F. Reidy  
Attorney For Applicants  
Registration No. 39,340

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-7320  
Fax: (858) 678-8233

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
0073-01-USAPPLICATION NO.  
TBA

APPLICANT(S)

S. Bender et al.

FILING DATE

Herewith

GROUP

1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,621,082					
	AB1	6,020,336					
	AC1	6,046,205					
	AD1	3,862,958					
	AE1	5,612,360					
	AF1	5,733,920					
	AG1	4,826,987					
	AH1	4,500340					
	AI1						
	AJ1						
	AK1						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 97/34876					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AM1	WO 97/03967					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AN1	WO 96/23783					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AO1	EP 0666 270 A2					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AP1	WO 97/16447					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AQ1	EP 0 731 385					<input type="checkbox"/> Yes <input type="checkbox"/> No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	Merenmies, J., Parada, L.F., Henkemeyer, M., Cell Growth & Differentiation, 8, 3-10 (1997)
	AS	<u>1</u>	Folkman, Nature Med., 1, 27-31 (1995)
	AT	<u>1</u>	Strawn et al., Cancer Research, 56, 3540-3545 (1996)
	AU	<u>1</u>	Lin et al., J. Med. Chem., 15 (6), 615-618, 1972
	AV	<u>1</u>	Rosowsky et al., J. Med. Chem., Vol. 31, 763-768, 1988

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM P 449

ATTY. DOCKET N

0073-01-US

APPLICATION NO:

TBA

INFORMATION DISCLOSURE STATEMENT

APPLICANT(S)

Bender et al.

FILING DATE

GROUP

Herewith

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2						
	AB2						
	AC2						
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	WO 99/21845					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AM2	WO 96/14843					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AN2	WO 99/06540					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AO2	WO 97/42949					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AP2	WO 98/17662					<input type="checkbox"/> Yes <input type="checkbox"/> No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>2</u>	Millauer et al., Cancer Research, 56, 1615-1620 (1996)
	AS	<u>2</u>	Yoshiji et al., Cancer Research, 57, 3924-3928 (1997)
	AT	<u>2</u>	Mohammad et al., EMBO Journal, 17, 5896-5904 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with 37 CFR 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT

APPLICANT(S)

Bender et al.

FILING DATE

GROUP

Herewith

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3						
	AB3						
	AC3						
	AD3						
	AE3						
	AF3						
	AG3						
	AH3						
	AI3						
	AJ3						
	AK3						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	WO 99/02162					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AM3	WO 99/43675					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AN3	WO 99/43676					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AO3	WO 98/33798					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AP3	WO 99/15500					<input type="checkbox"/> Yes <input type="checkbox"/> No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Maisonpierre et al., Science, 277, 55-60 (1997)
	AS	<u>3</u>	Science, 274, 1643-1677 (1996)
	AT	<u>3</u>	Hall et al., Adv. Cancer Res., 68, 67-108 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449			ATTY. DOCKET NO. 0073-01-US	APPLICATION NO. TBA
INFORMATION DISCLOSURE STATEMENT			APPLICANT(S) Bender et al.	
			FILING DATE Herewith	GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA4						
	AB4						
	AC4						
	AD4						
	AE4						
	AF4						
	AG4						
	AH4						
	AI4						
	AJ4						
	AK4						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL4	WO 99/17769					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AM4	WO 99/24416					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AN4	WO 99/23077					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AO4	WO 94/14780					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AP4	WO 98/03487					<input type="checkbox"/> Yes <input type="checkbox"/> No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	4	Kamb, Trends in Genetics, 11, 136-140 (1995)
	AS	4	Kamb et al., Science, 264, 436-440 (1994)
	AT	4	Webster, Exp. Opin. Invest. Drugs, 7, 865-887 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
0073-01-US  
APPLICANT(S)APPLICATION NO.  
TBA  
Bender et al.FILING DATE  
Herewith

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA5						
	AB5						
	AC5						
	AD5						
	AE5						
	AF5						
	AG5						
	AH5						
	AI5						
	AJ5						
	AK5						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL5	WO 98/38168					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AM5	WO 99/43663					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AN5	JP 63030563 A2					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AO5	WO 99/59959					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AP5	WO 96/30015					<input type="checkbox"/> Yes <input type="checkbox"/> No
	AQ5	EP 0767172					<input type="checkbox"/> Yes <input type="checkbox"/> No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Stover, et al., Curr. Opin. Drug Disc. Dev. 2, 274-285 (1999)
	AS	<u>5</u>	Gray et al., Curr. Med. Chem., 6, 859-875 (1999)
	AT	<u>5</u>	Sielecki, et al., J. Med. Chem., 43, 1-18 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSED IN CITATION  
(Use several sheets if necessary)

Applicant(s)  
S. Bender et al.

Filing Date

Herewith

Group Art Unit

1614

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AA6	Crews, et al., Curr. Opin. Chem Biol., 4, 47-53 (2000)
AB6	Buolamwini, Curr. Pharm. Des., 6, 379-392 (2000)
AC6	Rosania, et al., Exp. Opin. Ther. Pat., 10, 215-230 (2000)
AD6	O'Connor, Cancer Surveys, 29, 151-182 (1997)
AE6	Nurse, Cell, 91, 865-867 (1997)
AF6	Hartwell et al. Science, 266, 1821-1828 (1994)
AG6	Hartwell et al., Science, 246, 629-634 (1989)
AH6	Bunz et al., Science, 28, 1497-1501 (1998)
AI6	Winters et al., Oncogene, 17, 673-684 (1998)
AJ6	Thompson, Oncogene, 15, 3025-3035 (1997)
AK6	Peng et al. Science, 277, 1501-1505 (1997)
AL6	Sanchez et al., Science, 277, 1497-1501

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance or not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSED  
(Use several sheets if necessary)

Applicant(s)  
S. Bender et al.

Filing Date  
Herewith

Group Art Unit  
1614

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	AA7	Weinert, Science, 277, 1450-1451 (1997)
	AB7	Walworth et al., Nataure, 363, 368-371 (1993)
	AC7	Al-Khodairy et al., Molec. Biol. Cell, 5, 147-160 (1994)
	AD7	Zeng, et al., Nature, 395, 507-510 (1998)
	AE7	Matsuoka, Science, 282, 1893-1897 (1998)
	AF7	Bolen, Oncogene, 8, 2025-2031 (1993)
	AG7	McMahon et al., Current Opinion in Drug Discovery & Development, 1, 131-146 (1998)
	AH7	Strawn et al., Exp. Opin. Invest. Drugs, 7, 553-573 (1998)
	AI7	Adams et al., Curr. Opin. Drug Disc. Dev., 2, 96-109 (1999)
	AJ7	Toledo et al., Curr. Med. Chem., 6, 775-805 (1999)
	AK7	Garcia-Echeverria, et al., Med. Res. Rev., 20, 28-57 (2000)
	AL7	Bertolini et al., J. Med. Chem., 40, 2011-2016 (1997)

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance. Do not consider. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSED CITATION  
(Use several sheets if necessary)

Applicant(s)  
S. Bender et al.

Filing Date  
Herewith

Group Art Unit

1614

EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AA8	Shan, et al., J. Pharm. Sci., 86 (7), 765-767
AB8	Bagshawe, Drug Dev. Res., 34, 220-230 (1995)
AC8	Bodor, Advances in Drug Res., 13, 224-331 (1984)
AD8	Bundgaard, Design of Prodrugs (Elsevier Press 1985)
AE8	Larsen, Design and Application of Prodrugs, drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991)
AF8	Lee et al., Biochem, 23, 4255 (1984)
AG8	Parast C. et al., BioChemistry, 34, 16788-16801 (1998)
AH8	Jeffrey et al., Nature, 376, 313-320 (1995)
AI8	Still et al., J. Org. Chem., 43, 2923 (1978)
AJ8	J. Am. Chem. Soc. 120, 9722-23 (1998)
AK8	Forbes, et al., J. Med. Chem., 38, 2525 (1995)
AL8	J. Med. Chem., 40, 2866-2875 (1997)

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicant(s)  
S. Bender et al.

Filing Date

Herewith

Group Art Unit

1614

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AA9	Trova, M.P. et al., J. Med. Chem., 36, 580-590 (1993)
AB9	Mohammadi et al., Mol. Cell. Biol., 16, 977-989 (1996)
AC9	Rosenblatt et al., J. Mol. Biol., 230, 1317-1319 (1993)
AD9	Schang et al., J. Virol. 74, 2107-2120 (2000)
AE9	Braun-Dullaeus et al., Circulation, 98, 82-89 (1998)
AF9	Taniguchi et al., Nature Med., 5, 760-767 (1999)
AG9	Ann. Rev. Cell Dev. Biol., Vol. 13, pp. 261-291 (1997)
AH9	Lukas et al., Genes and Dev., Vol. 11, pp. 1479-1492 (1997)
AI9	Harper, Cancer Surv., Vol. 29, pp. 91-107 (1997)
AJ9	DelSal et al., Critical Rev. Oncogenesis, Vol. 71, pp. 127-142 (1996)
AK9	Nobori et al., Nature, Vol. 368, pp. 753-775 (1994)
AL9	Loda et al., Nature Medicine, Vol. 3 (1997), pp. 231-234
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSED IN CITATION  
(Use several sheets if necessary)

U U / S - U  
Applicant(s)  
S. Bender et al.

Filing Date

Herewith

Group Art Unit

1614

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AA10	Sherr, et al., Genes Dev., Vol. 13 (1999), pp. 1501-1512
AB10	Bandara, et al., Nature Biotechnology, Vol. 15 (1997), pp. 896-901
AC10	Chen, et al., Proceedings of the National Academy of Science, USA, Vol. 96 (1999) pp. 4325-4329
AD10	Cohen, et al., Proc. Natl. Acad. Sci. U.S.A., Vol. 95 (1998), pp. 14272-14277
AE10	Sedlacek et al., Int. J. Oncol., Vol. 9 (1996), pp. 1143-1168
AF10	Schow et al., Bioorg. Med. Chem. Lett., Vol. 7 (1997), pp. 2697-2702
AG10	Grant et al., Proc. Amer. Assoc. Cancer Res., Vol. 39 (1998), Abst. 1207
AH10	Legravend et al., Bioorg. Med. Chem. Lett., Vol. 8 (1998), pp. 793-798
AI10	Gray et al., Science, Vol. 281 (1998), pp. 533-538
AJ10	Chang, et al., Chemistry & Biology, Vol. 6 (1999), pp. 361-375
AK10	Ruetz et al., Proc. Amer. Assoc. Cancer Res., Vol. 39 (1998), Abst. 3794
AL10	Meyer et al., Proc. Amer. Assoc. Cancer Res., Vol. 39 (1998), Abst. 3794

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSED IN CITATION  
(Use several sheets if necessary)

Applicant(s)  
S. Bender et al.

Filing Date

Herewith

Group Art Unit

1614

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AA11	Owa, et al., J. Med. Chem., Vol. 42 (1999), pp. 3789-3799
AB11	Luzzio, et all, Proc. Amer. Assoc. Cancer Res., Vol. (1999), Abst. 4102
AC11	Schultz, et al., J. Med. Chem. Vol. (1999), pp. 2909-2919
AD11	Seitz, et al., 218th ACS Natl. Mtg (Aug. 22-26, 1999, New Orleans), Abst MEDI 316
AE11	International Search Report from the European Patent Office for PCT Patent Application No. PCT/US01/01723, issued by the EPO on June 12, 2001.
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance not considered. Include copy of this form with next communication to applicant.